Akcea Therapeutics, Inc. announced the appointment of Amber Salzman to the Company’s Board of Directors, expanding the board to 11 members. Dr. Salzman has more than 30 years of experience in the pharmaceutical industry including serving as chief executive officer of several companies, both publicly traded and private. Salzman is the President and CEO of Ohana Biosciences. She previously served as the president and CEO of Adverum Biotechnologies and was a co-founder of Annapurna, SAS, where she served as president and CEO prior to its merger with Avalanche Biosciences to become Adverum. Salzman was also a member of the GlaxoSmithKline research and development executive team where she was responsible for operations in drug development across multiple therapeutic areas. In addition to her roles in industry, Salzman is the president of the Stop ALD Foundation.